Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWM0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $76,596
Award facts
- Contract value 100% obligated
- $76,596.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $76,596.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on January 27, 2026, with an ultimate completion date of January 28, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group has been registered in the System for Award Management since 2001 and maintains an extensive portfolio of branded and generic pharmaceuticals, biologics, vaccines, and medical consumables to support military healthcare facilities worldwide. Under the PPV-G GEN V master contract awarded in November 2025 with a $499.9 billion ceiling and completion date of December 31, 2036, the Defense Logistics Agency maintains the flexibility to issue firm fixed-price delivery orders for recurring pharmaceutical supply needs. This particular delivery order for Xtandi, a specialized oncology treatment, reflects the contractor's role as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQWM0?
SPE2DR26FQWM0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FQWM0 worth?
The government has obligated $76,596 on SPE2DR26FQWM0.
Is contract SPE2DR26FQWM0 an order under another contract?
Yes. SPE2DR26FQWM0 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWM0 competed?
The extent of competition for SPE2DR26FQWM0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award